Background: Thrombophilia is a condition that predisposes to a higher incidence of venous thromboembolisms (VTE), some also in atypical sites. Direct oral anticoagulants (DOACs) have proven to be effective in the treatment of deep vein thrombosis (DVT). However, their use can be sometimes challenging in particular settings of patients such as those with major thrombophilia - antithrombin, protein C and protein S deficiency, homozygous mutation of Factor V Leiden, homozygous mutation of Factor II G20210A, combined heterozygous mutation of factor V Leiden and Factor II G20210A - carrying a high thrombotic risk. Patients and Methods: At our Center, 45 patients with major thrombophilia were treated with DOACs: 33 after an initial treatment with vitamin K antagonists (VKA) and 12 as first-line therapy for VTE. The median follow-up of DOACs treatment was 29 months. Conclusions: No patient presented hemorrhagic or thrombotic complications during DOAC therapy. DOACs have proven to be effective and safe in this real-life series of patients with major thrombophilia.

Direct oral anticoagulants in patients affected by major congenital thrombophilia / Serrao, A.; Lucani, B.; Mansour, D.; Ferretti, A.; Baldacci, E.; Santoro, C.; Foa, R.; Chistolini, A.. - In: MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES. - ISSN 2035-3006. - 11:1(2019), p. e2019044. [10.4084/MJHID.2019.044]

Direct oral anticoagulants in patients affected by major congenital thrombophilia

Serrao A.;Lucani B.;Ferretti A.;Baldacci E.;Santoro C.;Foa R.;Chistolini A.
2019

Abstract

Background: Thrombophilia is a condition that predisposes to a higher incidence of venous thromboembolisms (VTE), some also in atypical sites. Direct oral anticoagulants (DOACs) have proven to be effective in the treatment of deep vein thrombosis (DVT). However, their use can be sometimes challenging in particular settings of patients such as those with major thrombophilia - antithrombin, protein C and protein S deficiency, homozygous mutation of Factor V Leiden, homozygous mutation of Factor II G20210A, combined heterozygous mutation of factor V Leiden and Factor II G20210A - carrying a high thrombotic risk. Patients and Methods: At our Center, 45 patients with major thrombophilia were treated with DOACs: 33 after an initial treatment with vitamin K antagonists (VKA) and 12 as first-line therapy for VTE. The median follow-up of DOACs treatment was 29 months. Conclusions: No patient presented hemorrhagic or thrombotic complications during DOAC therapy. DOACs have proven to be effective and safe in this real-life series of patients with major thrombophilia.
2019
Antithrombin-III; Direct oral anticoagulant; Familial thrombophilia; Protein C and S deficiency; Vitamin K antagonist
01 Pubblicazione su rivista::01a Articolo in rivista
Direct oral anticoagulants in patients affected by major congenital thrombophilia / Serrao, A.; Lucani, B.; Mansour, D.; Ferretti, A.; Baldacci, E.; Santoro, C.; Foa, R.; Chistolini, A.. - In: MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES. - ISSN 2035-3006. - 11:1(2019), p. e2019044. [10.4084/MJHID.2019.044]
File allegati a questo prodotto
File Dimensione Formato  
Serrao_Direct oral anticoagulants_2019.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.06 MB
Formato Adobe PDF
1.06 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1311661
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact